The historical rank and industry rank for Voyager Therapeutics's ROE % or its related term are showing as below:
VYGR'
s ROE % Range Over the Past 10 Years
Min: -97.83 Med: -50.33 Max: 89.61
Current: -52.71
During the past 13 years, Voyager Therapeutics's highest ROE % was 89.61%. The lowest was -97.83%. And the median was -50.33%.
VYGR's ROE % is ranked worse than 57.29% of 1255
companies
in the Biotechnology industry
Industry Median: -38.34
vs VYGR: -52.71
Voyager Therapeutics (NAS:VYGR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Voyager Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's ROE % distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Voyager Therapeutics (VYGR) has a ROE % of -60.45% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #719 out of 1255 companies in the Biotechnology industry, placing it in the top 57.3%.
Is Voyager Therapeutics' ROE % too high?
Voyager Therapeutics' current ROE % is -60.45%. Based on the distribution chart, Voyager Therapeutics ranks #719 out of 1255 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Voyager Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' ROE % compare to CRBU and OBIO?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #719 out of 1255 companies for ROE %. This places Voyager Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current ROE % is -60.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (VYGR) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $3.70 — trading 111.4% above its estimated fair value. The current ROE % is -60.45%. Voyager Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Voyager Therapeutics (VYGR), the current ROE % is -60.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (VYGR) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of $3.70 is trading 111.4% above its estimated GF Value™ of $1.75.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for VYGR:
ROE %: -60.45%
GF Value™: $1.75 vs. price of $3.70 (111.4% above fair value)
No single metric tells the full story. See the VYGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
55GF Score
Get the complete analysis for VYGR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYGR has been successfully added to your 
